000 Currently only 10% of trauma cases get blood transfusions in the field. With better storage potential and no need for blood typing this could be increased to 100% (a factor of 10!). This is the potential usage in 1995. In order to project the numbers forward to 2000 (the date of product release)‚ we must estimate population growth. The elderly population (65 and older)‚ which currently receives 40% of all acute blood loss transfusions‚ is expected to double by 2030. Assuming linear
Free Blood Blood transfusion Surgery
Egypt. It is enterically transmitted virus. However other modes of transmission like blood transfusion is not excluded. No reports are available from Egypt about the prevalence of hepatitis E specific immunoglobulins G and M in children with multiple blood transfusion history. Aim: To Study the prevalence of antibodies specific to HEV either G or M among Egyptian children with history of multiple blood transfusions. Material and Method: The study included 30 children with chronic renal impairement
Premium Blood transfusion Hepatitis
was hemodynamically stable at the scene of the accident‚ but states he is unaware of what happened to him. The patient states he has a past medical history of asthma since age five and has no previous surgeries. Patient states he does not want any blood containing products or alternative treatments based on
Premium Health care provider Health care Patient
others have a difficult life circumstances that limits the options of treatments‚ and that can be the reason behind the fact that there is people out in the world deny medical treatment on purpose. Some ethics groups for example do not allow blood transfusion such as‚ Jehovah’s Witness. Some people do not have the time to go for regular checkups or regular treatment sessions. Anthropologists
Premium Blood transfusion Case study Physician
Exhibit 4: Financial Projections – Sensitivity Analysis 15 Executive Summary In 1998‚ Biopure Corporation is one of the three legitimate contenders in the emerging field of “blood substitutes”. Biopure has invested $200M on the R&D on blood substitutes in the past with its primary goal being the development of a human blood substitute ( Hemopure) but Its entry into animal market (Oxyglobin) had been some somewhat opportunistic. Oxyglobin got FDA approval recently‚ whereas the Hemopure will enter
Premium Blood Blood transfusion
Biopure Corporation have two new products that are Oxyglobin and Hemopure. Oxyglobin is the first blood substitute for the veterinary market and is ready for launch. Hemopure is another new blood substitute for the human market and will take two years to launch. Ted Jacobs‚ VP (Human Clinical Trials)‚ is concerned about creating an unrealistic price expectation for Hemopure by marketing Oxyglobin before Hemopure. Whereas‚ Andy Wright‚ VP (Veterinary Products)‚ believes that selling Oxyglobin has
Free Blood Blood transfusion Marketing
Richard Addington PHD Table of Contents 1. Executive Summary 2. Situation Analysis a. Human Blood Demand b. Human Blood Pricing c. RBC limitations 3. Internal Environment d. Strengths and weaknesses of Oxyglobin e. Strengths and weaknesses of Hemopure 4. External/Competitive Environment f. Baxter g. Northfield h. Biopure 5. Animal Blood Market 6. Marketing Plan i. Positioning j. Pricing k. Communication 7. Way Forward
Premium Blood Blood transfusion
PROFESSIONAL REGULATION COMMISSION What is PD 223? * The creation of the Professional Regulation Commission What is the date of approval? * June 22‚1973 What amended PD 223? * PD 223 was amended by PD 657 What is RA 8981? * The PRC Modernization Act of 2000 What is the composition of the PRC? * One full-time Chairperson * Two full-time commissioners What are the qualifications of commissioner of PRC? * At least 40 years of age * Holding a valid certificate of registration
Premium Blood donation Blood Blood bank
medicine W Intravenous fluids W Blood W Blood transfusion W Cholera W Bloodletting The Circulation Abstract The use of blood and intravenous fluid therapy is now considered routine therapy. The level of sophistication that we now perceive as standard has resulted from centuries of legends‚ religious beliefs‚ pseudo-science‚ nonscientific supposition‚ experimentation and error. The purpose of this article is to review the evolution of parenteral fluid and transfusion therapy through history. Data
Free Blood Blood transfusion Hematology
disease in which your body produces abnormally shaped red blood cells. They don’t last as long as normal‚ round red blood cells‚ which leads to anemia. Sickle cells contain abnormal hemoglobin that causes the cells to have a sickle shape. Sickle-shaped cells don’t move easily through your blood vessels. They’re stiff and sticky and tend to form clumps and get stuck in the blood vessels. The sickle cells also get stuck in blood vessels‚ blocking blood flow. This can cause pain and organ damage. Sickle cell
Premium Sickle-cell disease Red blood cell Hemoglobin